Please use this identifier to cite or link to this item:
|Title:||The bone and mineral disorder of children undergoing chronic peritoneal dialysis|
|Citation:||Borzych, D., Rees, L., Ha, I.S., Chua, A., Valles, P.G., Lipka, M., Zambrano, P., Ahlenstiel, T., Bakkaloglu, S.A., Spizzirri, A.P., Lopez, L., Ozaltin, F., Printza, N., Hari, P., Klaus, G., Bak, M., Vogel, A., Ariceta, G., Yap, H.K., Warady, B.A., Schaefer, F. (2010-12). The bone and mineral disorder of children undergoing chronic peritoneal dialysis. Kidney International 78 (12) : 1295-1304. ScholarBank@NUS Repository. https://doi.org/10.1038/ki.2010.316|
|Abstract:||The mineral and bone disorder of chronic kidney disease remains a challenging complication in pediatric end-stage renal disease. Here, we assessed symptoms, risk factors and management of this disorder in 890 children and adolescents from 24 countries reported to the International Pediatric Peritoneal Dialysis Network Registry. Signs of this disease were most common in North American patients. The prevalence of hyperphosphatemia increased with age from 6% in young infants to 81% in adolescents. Serum parathyroid hormone (PTH) was outside the guideline targets in the majority of patients and associated with low calcium, high phosphorus, acidosis, dialysis vintage and female gender. Serum calcium was associated with dialytic calcium exposure, serum phosphorus with low residual renal function and pubertal status. PTH levels were highest in Latin America and lowest in Europe. Vitamin D and its active analogs were most frequently administered in Europe; calcium-free phosphate binders and cinacalcet in North America. Clinical and radiological symptoms markedly increased when PTH exceeded 300 pg/ml, the risk of hypercalcemia increased with levels below 100 pg/ml, and time-averaged PTH concentrations above 500 pg/ml were associated with impaired longitudinal growth. Hence, the symptoms and management of the mineral and bone disorder of chronic kidney disease in children on peritoneal dialysis showed substantial regional variation. Our findings support a PTH target range of 100-300 pg/ml in the pediatric age group. © 2010 International Society of Nephrology.|
|Source Title:||Kidney International|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jul 19, 2018
WEB OF SCIENCETM
checked on Jun 25, 2018
checked on May 31, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.